Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.

Future oncology (London, England)（2023）

引用 0|浏览17

暂无评分

摘要

Overall, more than half of the participants (63%) in the MajesTEC-1 study responded to treatment with teclistamab despite previous myeloma treatment failures. NCT03145181, NCT04557098 (ClinicalTrials.gov).

查看译文

关键词

multiple myeloma,teclistamab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要